These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23596104)

  • 21. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
    Alimena G; Breccia M; Musto P; Cilloni D; D'Auria F; Latagliata R; Sanpaolo G; Gottardi E; Saglio G; Mandelli F
    Leuk Res; 2011 Apr; 35(4):504-7. PubMed ID: 20971509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
    Martin MG; Walgren RA; Procknow E; Uy GL; Stockerl-Goldstein K; Cashen AF; Westervelt P; Abboud CN; Kreisel F; Augustin K; Dipersio JF; Vij R
    Am J Hematol; 2009 Sep; 84(9):560-4. PubMed ID: 19650118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
    Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
    Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
    Rüter B; Wijermans PW; Lübbert M
    Cancer; 2006 Apr; 106(8):1744-50. PubMed ID: 16532502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
    Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
    J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS.
    Pierdomenico F; Esteves S; Almeida A
    Ann Hematol; 2013 Sep; 92(9):1201-6. PubMed ID: 23604468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
    Garcia-Manero G; Gore SD; Kambhampati S; Scott B; Tefferi A; Cogle CR; Edenfield WJ; Hetzer J; Kumar K; Laille E; Shi T; MacBeth KJ; Skikne B
    Leukemia; 2016 Apr; 30(4):889-96. PubMed ID: 26442612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
    Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; Rieger K; Fenk R; Germing U; Haas R; Kröger N; Kobbe G
    Leukemia; 2013 Jun; 27(6):1229-35. PubMed ID: 23314834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
    Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
    Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
    Douvali E; Papoutselis M; Vassilakopoulos TP; Papadopoulos V; Spanoudakis E; Tsatalas C; Kotsianidis I
    Leuk Res; 2013 Aug; 37(8):889-93. PubMed ID: 23726719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of lenalidomide in myelodysplastic syndromes.
    List A; Kurtin S; Roe DJ; Buresh A; Mahadevan D; Fuchs D; Rimsza L; Heaton R; Knight R; Zeldis JB
    N Engl J Med; 2005 Feb; 352(6):549-57. PubMed ID: 15703420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azacitidine in lower-risk myelodysplastic syndromes.
    Santini V
    Leuk Res; 2009 Dec; 33 Suppl 2():S22-6. PubMed ID: 20004794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.
    Pappa V; Anagnostopoulos A; Bouronikou E; Briasoulis E; Kotsianidis I; Pagoni M; Zikos P; Tsionos K; Viniou N; Meletis J; Papadaki H; Kioumi A; Galanopoulos A; Vervessou EC; Poulakidas E; Karmas P; Karvounis K; Symeonidis A
    Int J Hematol; 2017 Feb; 105(2):184-195. PubMed ID: 27815858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Curative effects of cyclosporin A therapy upon myelodysplastic syndrome].
    Chen SC; Jiang B; Da WM; Gong M; Guan M
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(38):2711-5. PubMed ID: 17199984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.